LONDON, April 29, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Investor-Edge.com has issued free earnings review on Johnson & Johnson (NYSE: JNJ). On April 14, 2015, the company announced its financial results for Q1 FY15 (period ended March 29, 2015). Click on http://get.Investor-Edge.com/pdf/?c=Johnson%20and%20Johnson&d=29-Apr-2015&s=JNJ to read our free earnings review on Johnson & Johnson (Johnson and Johnson). During Q1 FY15, the company reported Worldwide sales to customers of $17.37 billion with net earnings of $4.32 billion and diluted net earnings per share (EPS) of $1.53. Chairman and CEO of Johnson & Johnson, Alex Gorsky, stated that the company delivered strong underlying growth in Q1 FY15 driven by new products and the strength of the core business. Our free coverage report can be accessed at:
During Q1 FY15, Johnson & Johnson's Worldwide sales to customers fell 4.1% Y-O-Y from $18.12 billion in Q1 FY14. Worldwide sales to customers for Q1 FY15 outperformed Bloomberg analysts' forecast of $17.31 billion. In Q1 FY15, the company's operational results increased 3.1%, while there was a negative impact from currency of 7.2%. In Q1 FY15, US sales to customers improved 5.9% Y-o-Y to $8.69 billion, whereas International sales to customers declined 12.4% Y-o-Y to $8.68 billion in the reported quarter. Further, excluding the net impact of acquisitions and divestitures, Worldwide sales grew 5.7% Y-O-Y, US sales increased 9.1% Y-O-Y, and international sales improved 3.0% Y-O-Y, on an operational basis and for the reported quarter.
In Q1 FY15, Johnson & Johnson's Worldwide Consumer sales decreased 4.7% to $3.39 billion from $3.56 billion in Q1 FY14. In the reported quarter, the company's Worldwide Pharmaceutical sales stood at $7.73 billion, up 3.0% from $7.50 billion in Q1 FY14. Further, Johnson & Johnson's Worldwide Medical Devices sales were $6.26 billion in Q1 FY15, a decrease of 11.4%, from $7.06 billion in Q1 FY14. Mr. Gorsky noted the continued robust growth of the Pharmaceutical business and the solid performance of Johnson & Johnson's Consumer brands. Free research on JNJ can be downloaded in PDF format at:
Johnson & Johnson's earnings before provision for taxes on income improved 2.8% in Q1 FY15 to $5.58 billion from $5.42 billion in Q1 FY14. However, in Q1 FY15, the company's net earnings fell 8.6% from $4.73 billion in Q1 FY14, while diluted EPS declined by 6.7% from $1.64, in the prior year's same quarter. Analysts from Bloomberg had expected the company's net earnings and diluted EPS for Q1 FY15 to be $3.98 billion and $1.40, respectively. Moreover, excluding after-tax intangible amortization expense and special items, adjusted net earnings for Q1 FY15 were $4.42 billion and adjusted diluted EPS were $1.56, representing decreases of 5.9% Y-o-Y and 4.3% Y-o-Y, respectively.
During Q1 FY15, Johnson & Johnson announced a binding offer from Cardinal Health to acquire its Cordis business for an aggregate value of $1.99 billion. Sign up and read the free analyst's notes on JNJ at:
Johnson & Johnson updated its adjusted EPS guidance for full-year FY15 to be between $6.04 and $6.19, reflecting further negative foreign currency movements. The company's guidance excludes the impact of after-tax intangible amortization expense and special items.
On the day of the earnings release, April 14, 2015, Johnson & Johnson's stock edged 0.03% lower to end the session at $100.52. Since then, the stock has witnessed a mixed momentum. On the last close, Tuesday, April 28, 2015, shares of the company finished at $100.74, up 0.16%, after vacillating between $99.31 and $100.95. A total of 7.48 million shares were traded which was below their three months average volume of 8.75 million shares. The stock has advanced 0.28% in the previous three trading sessions and 0.40% over the last one month. However, the company's shares have fallen by 0.73% in the past three months. Shares in Johnson & Johnson closed above their 50-day moving average of $100.72. Furthermore, the stock traded at a PE ratio of 16.99 and has a Relative Strength Index (RSI) of 50.03. Visit Investor-Edge and access the latest research on JNJ at:
Sneak Peek to Corporate Insider Trading
In the last one month, Johnson & Johnson has not reported any share transactions by insiders to the U.S. Securities and Exchange Commission (SEC). Complimentary in-depth research on JNJ is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.